Research Focus

Former Employee. MEDICINE; Research Stdy Specialist

Recent additions – View all

1. Circulating VEGF levels as a biomarker to clinical benefit to PTC299, the first inhibitor of VEGF synthesis

   Meeting Abstract

   George, C. P.; Luke, J. J.; Winkelman, J.; Cao, Y. T. K. H.; Shakes, L.; Donnelly, K.; Darby, C. H.; Davis, T. W.; Elfring, G. L.; Schwartz, G. K.
   Journal of Clinical Oncology (2012)

   Fulltext@MSK | Save
2. Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer

   Meeting Abstract

   Schwartz, G. K.; Dickson, M. A.; Callahan, L. A.; Darby, C. H.; Llorente, M.; Cao, Y.; Dials, H. J.; Miller, L. L.; Miao, H. H.
   Journal of Clinical Oncology (2010)

   Fulltext@MSK | Save